Im­muno­Gen gets $25M up­front for ADC ther­a­py; mi­Ra­gen adds Eu­ro­pean or­phan drug des­ig­na­tion; Pierre Fab­re buys some pre­clin­i­cal im­munother­a­pies

→  The Eu­ro­pean Com­mis­sion grant­ed or­phan drug des­ig­na­tion to mi­Ra­gen’s $MGEN MRG-106 for the treat­ment of cu­ta­neous T-cell lym­phoma (CT­CL). “The Eu­ro­pean or­phan drug des­ig­na­tion for MRG-106 is an­oth­er reg­u­la­to­ry mile­stone which we be­lieve fur­ther val­i­dates the med­ical need for nov­el ther­a­pies in the treat­ment of CT­CL,” said mi­Ra­gen pres­i­dent and CEO, William Mar­shall. It earned the FDA’s own or­phan des­ig­na­tion for treat­ment of my­co­sis fun­goides—the most com­mon sub­type of CT­CL—ear­li­er this year. The Boul­der, CO-based mi­croR­NA biotech found its way in­to the pub­lic mar­kets last No­vem­ber, re­verse merg­ing with strug­gling Sig­nal Ge­net­ics and gain­ing a $40 mil­lion round to fi­nance clin­i­cal work.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER